Results 151 to 160 of about 8,418,026 (404)
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Critique of Creativity: Precarity, Subjectivity and Resistance in the ‘Creative Industries’ [PDF]
234 p. : il., Tablas.Libro ElectrónicoLa creatividad siempre está en movimiento: surge, se establece en el ente colectivo, palidece y desaparece a veces en el olvido; renace, vuelve con innovaciones, se reformula y resurge iniciando de nuevo el ciclo.
Raunig, Gerald (Ed.) +2 more
core
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Business Model of Culture and Creative Industries Incubator in creating social innovation [PDF]
Monika Tomczyk +1 more
openalex +1 more source
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Research on the Marketing Strategy of Music Culture Industry Driven by New Media Platform [PDF]
Z A Li
openalex +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source

